Scholars@Duke

Use of bevacizumab after U.S. Food and Drug Administration (FDA) approval for first-line metastatic colorectal cancer (mCRC): A Cancer Outcomes Research & Surveillance Consortium (CanCORS) study

Publication ,  Journal Article
Zafar, Y; Grambow, SC; Abbott, DH; Schrag, D; Kolimaga, JT; Conner, LZ; Weeks, JC; Provenzale, D
Published in: Journal of Clinical Oncology
May 20, 2008
Published version (DOI) Publisher Link

Duke Scholars

Steven C. Grambow
Author Steven C. Grambow Biostatistics & Bioinformatics, Division of Biostatistics

Published In

Journal of Clinical Oncology

DOI

10.1200/jco.2008.26.15_suppl.6562

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2008

Volume

26

Issue

15_suppl

Start / End Page

6562 / 6562

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zafar, Y., Grambow, S. C., Abbott, D. H., Schrag, D., Kolimaga, J. T., Conner, L. Z., … Provenzale, D. (2008). Use of bevacizumab after U.S. Food and Drug Administration (FDA) approval for first-line metastatic colorectal cancer (mCRC): A Cancer Outcomes Research & Surveillance Consortium (CanCORS) study. Journal of Clinical Oncology, 26(15_suppl), 6562–6562. https://doi.org/10.1200/jco.2008.26.15_suppl.6562
Zafar, Y., S. C. Grambow, D. H. Abbott, D. Schrag, J. T. Kolimaga, L. Z. Conner, J. C. Weeks, and D. Provenzale. “Use of bevacizumab after U.S. Food and Drug Administration (FDA) approval for first-line metastatic colorectal cancer (mCRC): A Cancer Outcomes Research & Surveillance Consortium (CanCORS) study.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 6562–6562. https://doi.org/10.1200/jco.2008.26.15_suppl.6562.
Zafar Y, Grambow SC, Abbott DH, Schrag D, Kolimaga JT, Conner LZ, et al. Use of bevacizumab after U.S. Food and Drug Administration (FDA) approval for first-line metastatic colorectal cancer (mCRC): A Cancer Outcomes Research & Surveillance Consortium (CanCORS) study. Journal of Clinical Oncology. 2008 May 20;26(15_suppl):6562–6562.
Zafar, Y., et al. “Use of bevacizumab after U.S. Food and Drug Administration (FDA) approval for first-line metastatic colorectal cancer (mCRC): A Cancer Outcomes Research & Surveillance Consortium (CanCORS) study.” Journal of Clinical Oncology, vol. 26, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2008, pp. 6562–6562. Crossref, doi:10.1200/jco.2008.26.15_suppl.6562.
Zafar Y, Grambow SC, Abbott DH, Schrag D, Kolimaga JT, Conner LZ, Weeks JC, Provenzale D. Use of bevacizumab after U.S. Food and Drug Administration (FDA) approval for first-line metastatic colorectal cancer (mCRC): A Cancer Outcomes Research & Surveillance Consortium (CanCORS) study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2008 May 20;26(15_suppl):6562–6562.

Published In

Journal of Clinical Oncology

DOI

10.1200/jco.2008.26.15_suppl.6562

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2008

Volume

26

Issue

15_suppl

Start / End Page

6562 / 6562

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences